Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer

Published: Saturday, Nov 07, 2015



Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Belani says at this juncture, there is no  one “winner" amongst these treatments.

Identifying a group of patients that best benefit from anti–PD-1 treatments will be the key to better understanding these agents, says  Belani.


Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Belani says at this juncture, there is no  one “winner" amongst these treatments.

Identifying a group of patients that best benefit from anti–PD-1 treatments will be the key to better understanding these agents, says  Belani.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x